## UNDERSTANDING **BART**



The **B**RAC**A**nalysis® Large **R**earrangement **T**est (BART<sup>TM</sup>) was developed to identify additional mutations in both *BRCA1* and *BRCA2* that are not currently identified as part of Myriad's BRAC*Analysis* test. These mutations account for 6-10% of all gene mutations that cause Hereditary Breast and Ovarian Cancer (HBOC).

Based on your personal and family history, your healthcare provider has recommended the BART test for you.

This test will help your provider better understand your hereditary risk for cancer.





he National Comprehensive Cancer Network (NCCN), an alliance of 21 of the world's leading cancer centers, has updated their hereditary breast and ovarian cancer guidelines to recommend that large rearrangement testing (eg, BART) be included as part of *BRCA1* and *BRCA2* gene testing.

The BART test is an important advancement in identifying gene mutations that cause hereditary breast and ovarian cancer. Your healthcare provider believes this test is very important to help manage your hereditary risk for cancer.

Because BART was only recently added to the NCCN guidelines, many insurance companies have not yet adopted it as a covered test. While we expect broad insurance coverage in the near future, it is possible the BART test may not yet be covered by your health insurance company. If coverage is not yet available, Myriad will contact you and your healthcare provider to determine whether you would like to:

- Proceed with the testing
- Cancel the BART test
- Hold your DNA sample until insurance coverage is available (or December 31, 2012, whichever occurs first)

If your insurance does not yet cover the BART test and you decide to proceed with testing, Myriad will call you to discuss financial options that meet your needs. Myriad guarantees to work with you to reach a solution.

Myriad Promise





v.mysupport360.com